AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00555984
Drug: Sevoflurane + Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
Trial: NCT02418468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo indacaterol capsules for inhalation daily
Trial: NCT03450707
Drug: Thiamine 500 mg IV
RxNorm normalized name: thiamine 500 MG
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
Trial: NCT01127750
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00254566
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose 2.0 g oral
Trial: NCT03500146
Drug: Anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients prescribed medication for OAB
Trial: NCT01110746
Drug: Viaject 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100IU/mL administered subcutaneously
Trial: NCT02932904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine Placebo-matching Capsules.
Trial: NCT00699010
Drug: Acurox 5/30mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: followed by oxycodone 5mg with 48 hour washout
Trial: NCT01577758
Drug: MLN0264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0264 30-minute infusion on Day 1 of each treatment cycle
Trial: NCT03805022
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
Trial: NCT03805022
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
Trial: NCT03805022
Drug: At the discretion of the investigator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug at the discretion of the investigator.
Trial: NCT01966965
Drug: PIOLIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
Trial: NCT03935633
Drug: CN128 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron chelator， oral tablets
Trial: NCT03987893
Drug: PEG-3350 with Electolytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
Trial: NCT00311896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03437785
Drug: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Trial: NCT03437785
Drug: Placebo of the CKD-495 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the CKD-495 75mg Tab.
Trial: NCT03437785
Drug: Placebo of the CKD-495 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the CKD-495 150mg Tab.
Trial: NCT03437785
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Trial: NCT02122536
Drug: Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to which side of the face would be treated with Xeomin.
Trial: NCT02122536
Drug: Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to which side of the upper face would be treated with Botox
Trial: NCT01212718
Drug: FUFA
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
Trial: NCT02280590
Drug: Rosuvastatin(Cresnon®)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg
Trial: NCT02280590
Drug: Rosuvastatin(Crestor®)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg
Trial: NCT03880903
Drug: hypertonic saline and salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
Trial: NCT03880903
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
Trial: NCT01489072
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
Trial: NCT01489072
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
Trial: NCT01952756
Drug: Dummy Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice per day for 12 weeks
Trial: NCT02758392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo on Day 1.
Trial: NCT05277844
Drug: TKI
RxNorm normalized name: Catkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI
Trial: NCT02689258
Drug: HTX-011B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX- 011B (bupivacaine/meloxicam) via injection
Trial: NCT02689258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo via injection
Trial: NCT02689258
Drug: HTX-011A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX- 011A (bupivacaine/meloxicam) via injection
Trial: NCT02689258
Drug: HTX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-002 via combination
Trial: NCT01050985
Drug: Temsirolimus and capecitabine
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
Trial: NCT00696137
Drug: BEMA Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
Trial: NCT03823248
Drug: MoLuoDan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
Trial: NCT03823248
Drug: Folic Acid Tablet
RxNorm normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
Trial: NCT03823248
Drug: Folic Acid Tablet simulation
RxNorm normalized name: folic acid Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
Trial: NCT00694369
Drug: Comparator: etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg; 120 mg (once daily) over three days.
Trial: NCT00694369
Drug: Comparator: ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 2400 mg (600 mg Q6h) over three Days
Trial: NCT00694369
Drug: Comparator: acetaminophen + codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
Trial: NCT00694369
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo over three Days
Trial: NCT01899599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT04372602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Provided by Verastem
Trial: NCT01279057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Trial: NCT01356381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg bid
Trial: NCT03023085
Drug: BLI4700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI4700 bowel preparation
Trial: NCT03426176
Drug: ATD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Trial: NCT00496847
Drug: PERIOGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
Trial: NCT01709695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Trial: NCT03072485
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical diclofenac applied to the skin
Trial: NCT00911261
Drug: Oxymorphone Extended Release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER.
Trial: NCT00546611
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03254186
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
Trial: NCT02357940
Drug: Experimental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Colloidal Oatmeal Balm
Trial: NCT04122599
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin for prevent post stroke delirium
Trial: NCT01611181
Drug: Hemoboost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
Trial: NCT01611181
Drug: Kräuterblut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg iron, 20 ml twice daily.
Trial: NCT01611181
Drug: Ferrofumerat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ferrous sulphate as 1 tablet twice daily.
Trial: NCT04174911
Drug: BOL-DP-o-08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOL-DP-o-08 sublingual drops
Trial: NCT04174911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual drops
Trial: NCT04222712
Drug: TRS01 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed four times a day (QID)
Trial: NCT03979638
Drug: BLU-5937
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four escalating doses of BLU-5937 administered BID over the course of the study
Trial: NCT03979638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for BLU-5937
Trial: NCT00483964
Drug: Bacopa monnieri
RxNorm normalized name: BACOPA MONNIERI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00483964
Drug: Nardostachys jatamansi
RxNorm normalized name: Nardostachys chinensis root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00578942
Drug: Campath Purged Non-myeloablative ASCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45.
Trial: NCT05320991
Drug: Nacl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
Trial: NCT03664752
Drug: IDP-120 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-120 Gel, once-daily application
Trial: NCT03664752
Drug: IDP-120 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-120 Vehicle Gel, once-daily application
Trial: NCT03465878
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injection
Trial: NCT02750059
Drug: TDF/3TC/EFV only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
Trial: NCT00267527
Drug: CJC 1295
RxNorm normalized name: CJC-1295
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220376
Drug: SPM 907
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133874
Drug: SB-275833 ointment, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03995212
Drug: CR845 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CR845 1.0 mg administered twice daily
Trial: NCT03995212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo administered twice daily
Trial: NCT00128921
Drug: VELCADE™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.
Trial: NCT00062465
Drug: TwHF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231346
Drug: Berodual® Respimat® - inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00082433
Drug: Ixabepilone + Capecitabine
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
Trial: NCT00082433
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Trial: NCT01220271
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01220271
Drug: Radiation
RxNorm normalized name: Miaderm Radiation Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as approved
Trial: NCT01672476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04425746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00719836
Drug: SB1518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
Trial: NCT00343733
Drug: OraVescent Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01757119
Drug: Tardyferon 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration (2 tablets)
Trial: NCT00016952
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016952
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00098111
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02180516
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02180516
Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02722447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks
Trial: NCT01705288
Drug: intravenous narcotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given for pain management after surgery per physician orders
Trial: NCT01705288
Drug: standard anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalant or intravenous during surgery
Trial: NCT01705288
Drug: regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by spinal or epidural infusion
Trial: NCT01705288
Drug: Non-steroidal anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given for pain management after surgery
Trial: NCT02145039
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Trial: NCT01064791
Drug: mycophenolic acid + tacrolimus + standard of care medications
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
Trial: NCT01786629
Drug: SUPREP Bowel Prep Kit
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration prior to colonoscopy
Trial: NCT00417794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
Trial: NCT00232908
Drug: ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00144339
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01308190
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Trial: NCT02972216
Drug: Nolbaxol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04200248
Drug: RBM-007 Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBM-007 Injectable Solution
Trial: NCT04200248
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham intravitreal injection
Trial: NCT01262885
Drug: GSK2251052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet, dose levels detailed in Arm description
Trial: NCT01262885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT02313610
Drug: Qinbudan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
Trial: NCT02313610
Drug: Qinbudan Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
Trial: NCT01582997
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
Trial: NCT00294164
Drug: Serostim®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
Trial: NCT00294164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
Trial: NCT04498793
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.